Talphera Advances Nafamostat Study Amid Rising CRRT Market Projections

Talphera CEO Vince Angotti confirmed that the company has finished realigning its clinical sites, ensuring all target locations are now active. This operational milestone aligns with a favorable shift in the regulatory landscape, as the 2026 KDIGO guidelines now recognize nafamostat as an acceptable anticoagulant for continuous renal replacement therapy. This update represents a distinct change from prior clinical recommendations and strengthens the potential commercial path for the company’s lead candidate, Niyad.

Financially, the company reported a cash and investment balance of $17.1 million as of June 30, 2026. The net loss for the second quarter reached $4.3 million, compared to $3.5 million during the same period last year, a variance primarily driven by higher development expenses associated with the ongoing trial. Talphera recently regained compliance with Nasdaq’s $1 minimum bid price rule and plans to host an investor event to discuss future commercial opportunities as trial enrollment nears its final phase.